Brief: Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Assembly Modulator in Chronic Hepatitis B
25/06/2025 13:08
June 25 (Reuters) - Assembly Biosciences Inc ASMB.O: ASSEMBLY BIOSCIENCES REPORTS POSITIVE TOPLINE RESULTS FROM PHASE 1B CLINICAL TRIAL OF NEXT-GENERATION INVESTIGATIONAL CAPSID ASSEMBLY MODULATOR ABI-4334 IN CHRONIC HEPATITIS B ASSEMBLY BIOSCIENCES INC - ABI-4334 WELL-TOLERATED WITH FAVORABLE SAFETY PROFILE Source text: ID:nGNX86L08T Further company coverage: ASMB.O ((Reuters.Briefs@thomsonreuters.com;))